Volasertib

Research use only, not for human use.

Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively.

Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively; displays no inhibitory activity against a panel of >50 other kinases; inhibits proliferation of multiple cell lines derived from various cancer tissues, including HCT116 (EC50=23 nM) and NCI-H460 (EC50=21 nM),BRO (EC50=11 nM), and hematopoietic cancer cell HL-60 (EC50=32 nM); demonstrates marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.Blood Cancer Phase 3 Clinical

BI 6727;BI-6727;BI6727

Cell Cycle/DNA Damage

PLK

PLK1

Cancer

Blood cancer

755038-65-4

618.81

C34H50N8O3

>98% (HPLC)

10 mM in DMSO

O=C(N[C@H]1CC[C@@H](N2CCN(CC3CC3)CC2)CC1)C4=CC=C(NC(N=C5N(C(C)C)[C@@H]6CC)=NC=C5N(C)C6=O)C(OC)=C4

Benzamide, N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-

(-20℃)

With Ice Pack

≥ 2 years